Singapore, May 20 -- AstraZeneca and Roche Diagnostics Asia Pacific have announced a three-year Memorandum of Understanding to help advance digital pathology capabilities and elevate cancer care across nine Asia markets, a first in the region. This landmark collaboration aims to accelerate the adoption of AI-powered digital and computational pathology through educational and training initiatives and improve biomarker testing in breast and lung cancer.

Globally, nearly half of all breast cancer cases and over 60% of new lung cancer diagnoses occur in Asia. In breast cancer, almost half of Asian women present lower levels of HER2, while TROP2 is present in 82-90% of non-small cell lung cancer. Precise biomarker testing is hence key to guid...